Stock Price Quote

FDC LTD.

NSE : FDCBSE : 531599ISIN CODE : INE258B01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE354.30-4.25 (-1.19 %)
PREV CLOSE ( ) 358.55
OPEN PRICE ( ) 360.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4801
TODAY'S LOW / HIGH ( )353.05 362.40
52 WK LOW / HIGH ( )314.75 528.3
NSE354.20-4.55 (-1.27 %)
PREV CLOSE( ) 358.75
OPEN PRICE ( ) 359.55
BID PRICE (QTY) 354.20 (3)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 110958
TODAY'S LOW / HIGH( ) 352.85 362.85
52 WK LOW / HIGH ( )312.95 527.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-09 1940
Management Info
- Chairman Mohan A Chandavarkar - Managing Director
Registered Office

Address B-8,Midc Industrial Area,Waluj Dist,
Chhatrapati Sambhajinagar - (Aurangabad),
Maharashtra-431136

Phone 0240- 2554407 / 2554967 / 2554299

Email waluj@fdcindia.com

Website www.fdcindia.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,L B S Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

29Jun FDC informs about disclosure
FDC has informed that it enclosed disclosure under Regulation 29(2) of S..
29Jun FDC informs about disclosures
FDC has informed that the Exchange has received the disclosure under Reg..
18May FDC gets USFDA’s nod for Cefixime for
FDC has received abbreviated new drug application (ANDA) approval from U..
18May FDC informs about board meeting
FDC has informed that Board Meeting will be held on Wednesday, May 27, 2..
18May FDC informs about ANDA approval
FDC has informed that the Company has been granted ANDA approval by Unit..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit1320.22859.24
Gross Profit 1742.7 3783.64
Operating Profit 1901.84631.81
Net Sales 655121263.27

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Acutaas Chemicals (BSE)
peergroup  3233.45 (3.94%)
M.Cap ( in Cr)26472.62
Kwality Pharma (BSE)
peergroup  3444.75 (3.53%)
M.Cap ( in Cr)3574.34
Neuland Laboratories (BSE)
peergroup  23311.50 (0.38%)
M.Cap ( in Cr)29908.40
Ajanta Pharma (BSE)
peergroup  3675.15 (1.64%)
M.Cap ( in Cr)45924.32
Fredun Pharma (BSE)
peergroup  1547.75 (3.33%)
M.Cap ( in Cr)2559.68

Shareholding Pattern

PROMOTERS 69.66%
MUTUAL FUNDS/UTI 6.25%
NON-INSTITUTION 22.63%
FI/BANKS/INSURANCE 0.06%
GOVERNMENT 0%
FII 0%

About FDC Ltd.

FDC Ltd. was incorporated in the year 1940. Its today's share price is 354.3. Its current market capitalisation stands at Rs 5768.36 Cr. In the latest quarter, company has reported Gross Sales of Rs. 21372.97 Cr and Total Income of Rs.21756.3 Cr. The company's management includes Kishore Mukund Saletore, Charuta Nityanath Mandke, Vijay Nautamlal Bhatt, Vijay Maniar, Mahesh Bijlani, Nomita R Chandavarkar, Ameya A Chandavarkar, Ashok A Chandavarkar, Nandan M Chandavarkar, Mohan A Chandavarkar, Varsharani Katre.

It is listed on the BSE with a BSE Code of 531599 , NSE with an NSE Symbol of FDC and ISIN of INE258B01022. It's Registered office is at B-8,Midc Industrial Area,Waluj DistChhatrapati Sambhajinagar - (Aurangabad)-431136, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, RSM & Co, SR Batliboi & Associates, SR Batliboi & Co, SR Batliboi & Co LLP, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.